Tests TH9619 in adults with advanced solid tumors
Tests the drug TH9619 in adults with advanced solid cancers.
Plain-language title generated from the registry record
Registry title: Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Key facts
- Where
- Barcelona and Madrid, SpainSee the 2 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced colorectal, head and neck, non-small cell lung or gastric cancer who have already had chemotherapy for cancer that has spread or cannot be removed by surgery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced cancer confirmed by tissue examination: colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer, or gastric cancer (including gastroesophageal junction cancer).
- Earlier treatment
- Must have had at least one line of cytotoxic systemic therapy for metastatic or unresectable cancer.
Main reasons for not taking part
- Any clinically significant disorder, as judged by the investigator
Read by machine on 12 November 2026.
Where in Spain
- Vall d'Hebron Institute of OncologyBarcelona, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- One-carbon Therapeutics AB
- Trial code
- NCT07151040EU 2024-519639-40-00
- Record updated
- 28 January 2026
- Original description
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.Read full original descriptionShow less
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Inclusion: Must have given written informed consent; Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer)); Prior treatment with at least one line of cytotoxic systemic therapy for metastatic/unresectable cancer; Adult patients (≥18 years of age); Must be willing to comply with study procedures.
Exclusion: History or presence of any clinically significant disorders as judged by the Investigator.